Logo

Seagen Signs an Exclusive WW License Agreement with RemeGen to Develop and Commercialize Disitamab Vedotin

Share this

Seagen Signs an Exclusive WW License Agreement with RemeGen to Develop and Commercialize Disitamab Vedotin

Shots:

  • RemeGen to receive $200M up front for development and commercialization rights of disitamab vedotin outside of Remegen’s territory & ~$2.4B upon the achievement of milestones across multiple indications along with royalties on sales of the therapy in Seagen’s territory
  • RemeGen will retain development & commercialization rights of the therapy in Asia (Ex-Japan & Singapore). Seagen will be responsible for global development whereas RemeGen will fund and operationalize the portion of clinical trials & lead clinical development and regulatory submissions specific to its territory
  • The collaboration leverages companies' expertise in developing ADCs along with Seagen’s development capabilities

Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions